



To,

October 28, 2024

**National Stock Exchange of India Ltd.**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E),  
Mumbai- 400051

**Script Name:** MAITREYA

**ISIN:** INE0PLQ01011

**Sub: Outcome of the Board Meeting held on Monday, 28<sup>th</sup> October, 2024**

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. October 28, 2024, inter-alia considered and approved the following.:

1. Consider and approved the standalone and Consolidated unaudited financial results / Accounts of the Company for the Half year ended on September 30, 2024, along with the Limited Review Report:

The aforesaid Board Meeting commenced at 03:30 p.m. (IST) and concluded at 04:10 p.m. (IST).

We request you to kindly take the above on record.

Thanking You,

Yours faithfully,

For **Maitreya Medicare Limited**

**Chandan Chetnani**  
**Company Secretary & Compliance Officer**

**Maitreya Medicare Limited**

Address : Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat - 395007.

Ph. : 0261-2299000 | Reception : +91 82382 29900 | Email : maitreyaedicare@gmail.com

CIN : U24290GJ2019PLC107298



**Independent Auditors' Review Report on Half Year and Year To Date Standalone Unaudited Financial Results of Maitreya Medicare Limited (Formerly Known as Maitreya Medicare Private Limited) pursuant to the Regulation 33 Of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**Review Report**

**To the Board of Directors of  
Maitreya Medicare Limited**


**(Formerly Known as Maitreya Medicare Private Limited)**

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Maitreya Medicare Limited (Formerly Known as "Maitreya Medicare Private Limited")** (the "Company") for the Half Year ended September 30, 2024 and the year to date results for the period April 1, 2024 to September 30, 2024, ("the Statement ") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Saherwala & Co**  
Chartered Accountants  
FRN - 108969W



(CA Esmayeel O. Saherwala)  
Partner  
Membership No. - 122386  
UDIN - **24122386BKENIA9990**

Surat, October 28, 2024

**Maitreya Medicare Limited**  
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

(₹ in Lakhs)

Particulars	Half year ended		For the year ended March 31, 2024	For the year ended March 31, 2023
	September 30, 2024	September 30, 2023		
	Unaudited	Audited	Audited	Audited
I Revenue from operations	2,217.98	2,427.53	4,652.81	3,847.88
II Other income	14.28	5.14	22.27	56.32
III Total Revenue (I + II)	2,232.26	2,432.67	4,675.08	3,904.20
IV Expenses:				
(a) Cost of Raw Material Consumed	159.07	230.92	375.49	396.50
(b) Purchase of Stock-in-Trade	260.63	250.11	546.77	424.51
(d) Employee benefits expense	243.55	240.17	475.19	464.15
(e) Finance costs	38.35	38.66	73.90	56.75
(f) Depreciation and amortization expense	63.46	62.56	125.59	127.02
(g) Other expenses	1,281.08	1,241.70	2,612.66	1,855.00
Total Expenses	2,046.75	2,087.05	4,236.24	3,317.10
VI Prior-Period Items	-	-	-	3.24
VII Profit before tax (V- VI)	185.51	345.62	438.85	583.86
VIII Tax expense:				
(1) Current tax expense	49.77	99.24	119.94	155.34
(2) Deferred tax expense/(credit)	1.13	1.12	1.53	9.98
(3) Short/(Excess) provision of tax for earlier years	-	-	-	-
Dividend on Preference Shares	0	0	0	88.82
IX Profit from continuing operations (VII-VIII)	134.61	245.26	317.39	329.72
X Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	677.60	496.00	677.60	496.00
XI Reserves excluding revaluation reserves as per balance sheet of previous accounting year	1,943.09	623.82	382.27	-
XII Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each				
(Pre-bonus)				
- Basic				
- Diluted				
(Post-bonus)				
- Basic	1.99	4.94	4.68	6.65
- Diluted	1.99	4.94	4.68	6.65

For and on behalf of the Board of Directors

Narendra Singh Tanwar  
(Managing Director & CFO)  
DIN: 08459007

Place : Surat  
Date : 28/10/2024



Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024**

Notes to unaudited standalone financial results

- 1 The above unaudited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on October 28, 2024.
- 2 The Results for the half year ended September 30, 2024 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,
- 3 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 4 The figures for the half year ended September 30, 2024 are the unaudited published figures for the half year ended September 30, 2024 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 5 The figures for the half-year ended September 30, 2023 are audited published figures in respect of the half-year ended September 30, 2023 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 6 The comparative results for the year ended March 31, 2024 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 7 The comparative results for the year ended March 31, 2023 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2023 are audited unpublished figures in respect of the year ended March 31, 2023 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 8 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- 9 During the year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

Notes to unaudited standalone financial results

10 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Lakhs)	Amount utilised till September 30, 2024 (₹ in Lakhs)	Amount unutilised till September 30, 2024 (₹ in Lakhs)	Remarks (if any)
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	100.00	100.00	-	Remaining amount is kept with banks.
3	Funding the working capital requirements of the company	500.00	500.00	-	
4	General Corporate Expenses	74.46	74.46	-	
5	Public Issue Expenses	64.66	64.66	-	
Total		1,489.12	1,489.12	-	

For and on behalf of the Board of Directors

  
Narendra Singh Tanwar  
(Managing Director & CFO)  
DIN: 08459007



Place : Surat  
Date : 28/10/2024

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
**BALANCE SHEET AS ON 30th September 2024**  
CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000')

Particulars	Note No.	As at 30th September 2024	As at 31st March 2024
<b>I. EQUITY &amp; LIABILITIES</b>			
<b>(1) Shareholders' Funds</b>			
a) Share capital	1	121723.000	121723.00
b) Reserve & Surplus	2	194308.937	180847.08
c) Money received against share warrants		.00	.00
<b>(2) Share application money pending allotment</b>		.00	.00
<b>(3) Non-Current Liabilities</b>			
a) Long-term Borrowings	3	23400.78	27035.23
b) Deferred tax liability (Net)	4	6953.09	6839.92
c) Other long term Liabilities		.00	.00
d) Long term Provisions		.00	.00
<b>(4) Current Liabilities</b>			
a) Short-term Borrowings	5	15128.81	13600.70
b) Trade payables		.00	.00
(A) total outstanding dues of micro enterprises and small enterprises; and	6	6173.17	4436.14
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		18640.43	19064.62
c) Other current Liabilities	7	26485.88	19633.66
d) Short term Provisions	8	16970.37	11993.87
<b>Total</b>		<b>429784.48</b>	<b>405174.22</b>
<b>II. Assets</b>			
<b>(1) Non-current assets</b>			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment			
	9	116760.48	109209.12
(ii) Intangible Assets			
		151.73	166.29
b) Non Current Investments	10	75830.00	25924.10
c) Deferred tax asset (net)		.00	.00
d) Long term loans and advances	11	54224.75	41735.91
e) Other Non current assets	12	12865.57	18572.90
<b>(2) Current assets</b>			
a) Current Investments	13	422.15	10197.07
b) Inventories	14	4692.52	4685.09
c) Trade receivables	15	134656.08	130707.63
d) Cash & Cash equivalents	16	19330.72	56613.53
e) Short-term loans and advances	17	10216.89	1540.97
f) Other current assets	18	633.58	5821.60
<b>Total</b>		<b>429784.48</b>	<b>405174.22</b>

For MAITREYA MEDICARE LIMITED



*Narendra*  
NARENDRA TANWAR  
DIN - 0008459007  
MD AND CFO

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
**PROFIT AND LOSS STATEMENT FOR THE PERIOD ENDED ON 30th september 2024**  
CIN No. - U24290GJ2019PTC107298  
(Currency: Rs in '000')

Particulars	Note No.	As at 30th September 2024	As at 31st March 2024
I. Revenue from operations	19	221798.17	465280.57
II. Other Income	20	1428.42	2226.57
<b>III. Total Income (I+II)</b>		<b>223226.590</b>	<b>467507.14</b>
<b>IV. Expenses:</b>			
Consumption of Stores and Pharmacy	21	15906.70	37548.89
Purchase of stock-in-Trade	22	26063.31	54677.42
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	23	61.34	2663.80
Employee benefit expense	24	24355.29	47518.56
Financial Costs	25	3835.01	7389.84
Depreciation and amortization expense	26	6345.65	12559.25
Other expense	27	128107.76	261266.40
<b>Total Expense</b>		<b>204675.06</b>	<b>423624.16</b>
<b>V. Profit Before exceptional and extraordinary items and tax</b>	(III-IV)	<b>18551.53</b>	<b>43882.99</b>
<b>VI. Exceptional Items</b>			
Adjustment of GST Liability		.00	.00
Reversal of Previous Year Income Tax/TCS		.00	.00
Rectification of Previous Year Mutual Fund Value		.00	.00
Rectification of Depreciation		.00	.00
Gratuity Prior Period		.00	.00
Operating lease Prior Period Adjustment		.00	.00
<b>VII. Profit Before extraordinary items and tax (V-VI)</b>		<b>18551.53</b>	<b>43882.99</b>
<b>VIII. Extraordinary Items</b>			
<b>IX. Profit before tax (VII-VIII)</b>		<b>18551.53</b>	<b>43882.99</b>
<b>X. Tax expense:</b>			
(1) Current Tax	28	4976.50	11993.87
(2) Deferred Tax	29	113.17	153.08
(3) MAT Credit Entitlement		.00	.00
<b>XI. Profit(Loss) from the period from continuing operations</b>		<b>13461.86</b>	<b>31736.04</b>
<b>XII. Profit/(Loss) from discontinuing operations</b>		<b>.00</b>	<b>.00</b>
<b>XIII. Tax expense of discontinuing operations</b>		<b>.00</b>	<b>.00</b>
<b>XIV. Profit/(Loss) from discountinuing operations (XII- XIII)</b>		<b>.00</b>	<b>.00</b>
<b>XV. Profit/Loss for the period (XI+XIV)</b>		<b>13461.86</b>	<b>31736.04</b>
<b>XVI. Earning per equity share:</b>	30		
Basic		1.99	4.16
Diluted		1.99	4.16

Significant Accounting Policies and Notes on Accounts as per annexed

31

For MAITREYA MEDICARE LIMITED




*Narendra*  
**NARENDRA TANWAR**  
DIN - 0008459007  
MD AND CFO



**MAITREYA MEDICARE LIMITED**  
(formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
**CASH FLOW STATEMENT**  
CIN No. - U24290GJ2015PTC107298  
(Currency: Rs in '000')

PARTICULARS	H: If Year Ended 30-09-2024	Year Ended 31-03-2024
<b>A. Cash Flow from Operating Activities:</b>	<b>18551.53</b>	<b>43882.99</b>
Profit Before exceptional and extraordinary items and tax Adjustments for :		
Depreciation	6345.65	12559.25
Interest Income	-180.77	-1245.61
Gratuity	561.68	1285.90
Interest & Finance Charges Paid	3835.01	7389.84
Profit on sale of Investment	225.09	258.04
Sundry Balance Write back	.00	11344.52
	<b>10786.66</b>	<b>31591.93</b>
Operating Profit before Working Capital Changes	<b>29338.19</b>	<b>75474.92</b>
Adjustments for :		
Increase / Decrease in Inventories	-7.43	3300.00
Increase / Decrease in Short-term loans and advances	-8675.93	1758.51
Increase / Decrease in Trade Receivables	-3948.45	-49459.28
Increase / Decrease in Trade Payables	1312.85	-12868.35
Increase / Decrease in other Current Assets	-5188.02	-1634.78
Increase / Decrease in Other Non Current Assets	5145.65	-3067.30
Increase/Decrease in Provision	4976.50	-2818.33
Increase/Decrease in short term Borrowings	1528.11	734.08
Increase/Decrease in other current liabilities	6852.22	3722.15
Cash Generated from Operations	<b>12371.54</b>	<b>-60333.29</b>
Direct Taxes Paid (Net)	<b>41709.73</b>	<b>15141.63</b>
<b>Net Cash in flow in Operating Activities</b>	<b>14392.03</b>	<b>17725.00</b>
<b>B. Cash Flow from Investing Activities:</b>	<b>27317.70</b>	<b>-2583.37</b>
Purchases of Fixed assets	-13882.44	-6798.15
Purchase of Investment	-44656.072	-33679.79
Capital Government Grant of Fixed Assets	.00	.00
Loans given to Associates and Subsidiaries	-3073.30	-20730.00
Loans given to Others	.00	.00
Repayment of Loans given to Associates and Subsidiaries	.00	.00
Interest Income	180.77	1245.61
Gain on Sale of Investment	.00	.00
Sale of Investment	4300.00	4300.00
<b>Net Cash used in Investing Activities</b>	<b>-57131.05</b>	<b>-55662.33</b>
	<b>-57131.05</b>	<b>-55662.33</b>
	<b>Total B</b>	<b>Total B</b>



<b>C. Cash Flow from Financing Activities:</b>			
Issue of Equity Capital			18160.00
Share Premium			114445.07
Dividend			-3561.40
Issue of Preference Shares			.00
Redemption of Preference shares			-3400.00
Repayment of Borrowing			-18610.29
Interest & Finance Charges Paid			-7026.13
<b>Net Cash from Financing Activities</b>		-7469.46	100007.26
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>		-7469.46	100007.26
Opening Cash and Cash equivalents		-37282.80	41761.56
<b>Closing Cash and Cash equivalents</b>		56613.52	14851.96
		19330.72	56613.52

**Notes :**

- (i) Figures in brackets represent outflow.  
(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act, 2013  
(iii) Cash and Cash Equivalents represent cash and bank balances.

For MAITREYA MEDICARE LIMITED



NARENDRA TANWAR

DIN - 0008459007  
MD AND CFO





**Independent Auditors' Review Report on Half Year and Year To Date Consolidated Unaudited Financial Results of Maitreya Medicare Limited (Formerly Known as Maitreya Medicare Private Limited) pursuant to the Regulation 33 Of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**Review Report**

**To the Board of Directors of**

**Maitreya Medicare Limited**

**(Formerly Known as Maitreya Medicare Private Limited)**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Maitreya Medicare Limited (Formerly Known as "Maitreya Medicare Private Limited")** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the Half year ended September 30, 2024 and the year to date results for the period April 1, 2024 to September 30, 2024, ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities:

Maitreya Medicare Limited	Holding Company
Maitreya Lifescience Private Limited	Wholly own Subsidiary
Maitreya Hospital Private Limited	Wholly own Subsidiary
Tulip Agility Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of 3 subsidiaries as included in the consolidated unaudited financial results, whose interim financial results reflect as follows:

(Rs. In thousands)

Particulars	For the year ended		For the year ended	
	September 30, 2024	September 30, 2023	March 31, 2024	March 31, 2023
Total Revenue	26007.12	5182.71	45684.05	15078.24
Net Profit/(Loss)	3266.18	1106.70	-10749.78	670.59

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

For **Saherwala & Co**  
Chartered Accountants  
FRN - 108969W



(CA Esmayeel O. Saherwala)  
Partner

Membership No. - 122386  
UDIN - 24122386BKEN132597



Surat, October 28, 2024

**Maitreya Medicare Limited**  
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

(₹ in lakhs)

Particulars	Half Year ended		For the year ended	
	September 30, 2024	September 30, 2023	March 31, 2024	March 31, 2023
	Unaudited	Audited	Audited	Audited
I Revenue from operations	2,436.28	2,479.36	4,780.35	3,938.00
II Other income	18.98	5.14	27.22	56.90
III Total Revenue (I + II)	2,455.26	2,484.50	4,807.57	3,994.90
IV Expenses:				
(a) Cost of Raw Material Consumed	159.07	231.14	376.69	396.60
(b) Purchase of Stock-in-Trade	261.90	250.11	561.75	424.51
(d) Employee benefits expense	283.47	248.96	534.84	484.25
(e) Finance costs	45.10	38.66	84.24	56.75
(f) Depreciation and amortization expense	66.10	63.61	127.22	129.14
(g) Other expenses	1,408.75	1,270.69	2,711.71	1,914.63
Total Expenses	2,229.05	2,126.10	4,420.51	3,399.05
VI Prior-Period Items			2.94	3.24
VII Profit before tax (V- VI)	226.21	358.40	390.00	592.61
VIII Tax expense:				
(1) Current tax expense	57.83	101.01	119.94	157.40
(2) Deferred tax expense/(credit)	1.15	1.07	1.48	9.98
(3) Short/(Excess) provision of tax for earlier years	-	-	-	-
	58.98	102.08	121.42	167.38
IX Profit from continuing operations (VII-VIII)	167.23	256.32	268.58	425.23
X Minority Interest				
XI Profit attributable to owners of the equity (IX-X)	167.23	256.32	268.58	425.23
XII Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	67,760.00	49,600.00	67,760.00	49,600.00
XIII Reserves excluding revaluation reserves as per balance sheet of previous accounting year				
XIV Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each				
(Pre-bonus)				
- Basic				
- Diluted				
(Post-bonus)				
- Basic				
- Diluted				

For and on behalf of the Board of Directors

Narendra Singh Tanwar  
(Managing Director & CFO)  
DIN: 08459007

Place : Surat  
Date : 28/10/2024



Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

Notes to unaudited consolidated financial results

- 1 The above unaudited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on October 28, 2024.
- 2 The Results for the Half year ended September 30, 2024 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,
- 3 The results includes results of 2 wholly owned subsidiaries - Maitreya Hospital Private Limited and Maitreya Lifescience Private Limited and 1 subsidiary - Tulip Agility Private Limited.
- 4 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 5 The figures for the half year ended September 30, 2024 are the unaudited published figures for the half year ended September 30, 2024 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 6 The figures for the half-year ended September 30, 2023 are audited published figures in respect of the half-year ended September 30, 2023 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 7 The comparative results for the year ended March 31, 2024 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 8 The comparative results for the year ended March 31, 2023 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2023 are audited unpublished figures in respect of the year ended March 31, 2023 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 9 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- 10 During the year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298


STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

Notes to unaudited consolidated financial results

11 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Lakhs)	Amount utilised till March 31, 2024 (₹ in Lakhs)	Amount unutilised till March 31, 2024 (₹ in Lakhs)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	750.00	750.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	100.00	100.00	-	
3	Funding the working capital requirements of the company	500.00	500.00	-	
4	General Corporate Expenses	74.46	74.46	-	
5	Public Issue Expenses	64.66	64.66	-	
Total		1,489.12	1,489.12	-	

For and on behalf of the Board of Directors

  
Narendra Singh Tanwar  
(Managing Director & CFO)  
DIN: 08459007



Place : Surat  
Date : 28/10/2024

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
**CONSOLIDATED BALANCE SHEET AS ON 30th September 2024**  
CIN No. - U24290GJ2019PTC107298  
(Currency: Rs in '000')

		CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
Particulars	Note No.	As at 30th September 2024	As at 31st March 2024
<b>I. EQUITY &amp; LIABILITIES</b>			
<b>(1) Shareholders' Funds</b>			
a) Share capital	1	122203	121723
b) Reserve & Surplus	2	197428	180704
c) Money received against share warrants	3		
d) Minorities Interest / Capital Reserve	2.1	8547	1096
<b>(2) Share application money pending allotment</b>			
<b>(3) Non-Current Liabilities</b>			
a) Long-term Borrowings	4	41510	43424
b) Deffered tax liability (Net)	5	7086	6971
c) Other long term Liabilities			
d) Long term Provisions			
<b>(4) Current Liabilities</b>			
a) Short-term Borrowings	6	15129	13601
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and small enterprises.	7	6173	4436
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		20925	26989
c) Other curent Liabilites	8	33046	27664
d) Short term Provisions	9	17777	11994
<b>Total</b>		<b>469823</b>	<b>438602</b>





<b>II. Assets</b>			
<b>(1) Non-current assets</b>			
<b>(a) Property, Plant and Equipment</b>			
(i) Gross Block		209745	195866
(ii) Depreciation	10	59213	52660
(iii) Net Block		150532	143206
b) Non Current Investments	11	10	4510
c) Deffered tax asset (net)			
d) Long term loans and advances	12	34317	23386
e) Other Non current assets	13	18586	14293
<b>(2) Current assets</b>			
a) Current Investments	14	422	10197
b) Inventories	15	5673	6070
c) Trade receivables	16	137585	136954
d) Cash & Cash equivalents	17	81359	65569
e) Short-term loans and advances	18	40691	28554
f) Other current assets	19	648	5863
<b>Total</b>		<b>469823</b>	<b>438602</b>

For MAITREYA MEDICARE LIMITED



*Narendra Tanwar*

NARENDRA TANWAR

DIN - 0008459007

MD AND CFO

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
Statement of Consolidated Profit & Loss for the Half year ended 30th September 2024  
CIN No. - U24290GJ2019PTC107298  
(Currency: Rs in '000')

Particulars	Note No.	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
		As at 30th September 2024	As at 31st March 2024
I. Revenue from operations	20	243628.40	477630.36
II. Other Income	21	1898.15	2721.86
<b>III. Total Revenue (I+II)</b>		<b>245526.55</b>	<b>480352.22</b>
<u>IV. Expenses:</u>			
Cost of materials consumed	22	15906.70	37669.13
Purchase of stock-in-Trade	23	26190.28	52923.15
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	24	465.66	2404.58
Employee benefit expense	25	28346.52	50968.57
Financial Costs	26	4509.73	8424.23
Depreciation and amortization expense	27	6610.36	12722.41
Other expense	28	140874.84	273686.51
<b>Total Expense</b>		<b>222904.08</b>	<b>438798.79</b>
V. Profit Before exceptional and extraordinary items and tax	(III-IV)	<b>22622.47</b>	<b>41553.44</b>
VI. Exceptional Items		.00	.00
Adjustment of GST Liability		.00	.00
Reversal of Previous Year Income Tax/TCS		.00	.00
Rectification of Previous Year Mutual Fund Value		.00	.00
Rectification of Depreciation		.00	-293.88
Gratuity Prior Period		.00	.00
Operating lease Prior Period Adjustment		.00	.00
VII. Profit Before extraordinary items and tax (V-VI)		22622.47	41847.31
VIII. Extraordinary Items			
<b>IX. Profit before tax (VII-VIII)</b>		<b>22622.47</b>	<b>41847.31</b>



X. Tax expense:			
(1) Current Tax	29	4976.50	11993.87
(2) Deferred Tax	30	115.31	158.09
(3) MAT Credit Entitlement			
XI. Profit(Loss) from the period from continuing operations		17530.65	29695.35
XII. Profit/(Loss) from discontinuing operations		.00	.00
XIII. Tax expense of discontinuing operations		.00	.00
XIV. Profit/(Loss) from discountinuing operations (XII- XIII)		.00	.00
XV. Profit/Loss for the period (XI+XIV)		17530.65	29695.35
XVI. Earning per equity share:	31		
Basic		2.30	4.15
Diluted		2.30	4.15

For MAITREYA MEDICARE LIMITED



*Narendra*

NARENDRA TANWAR  
DIN - 0008459007  
MD AND CFO

**MAITREYA MEDICARE LIMITED**  
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)  
**CONSOLIDATED BALANCE SHEET AS ON 30th September 2024**  
CIN No. - U24290GJ2019PTC107298  
(Currency: Rs in '000')

PARTICULARS	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
	As at 30th September 2024	As at 31st March 2024
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before tax	22622.47	41553.44
Adjustments for :		
Depreciation	6610.36	12722.41
Interest Income	-650.51	-1522.05
Interest & Finance Charges Paid	4467.82	8420.41
Gratuity	561.68	1285.90
Profit on sale of Investment	225.09	258.04
Sundry Balance Write back	.00	11344.52
<b>Sub Total</b>	11214.44	32509.24
Operating Profit before Working Capital Changes	33836.91	74062.67
Adjustments for :		
Increase / Decrease in Inventories	396.89	3040.88
Increase / Decrease in Short-term loans and advances	-8675.93	1758.51
Increase / Decrease in Trade Receivables	-4943.56	-54606.17
Increase / Decrease in Trade Payables	-14.23	-9563.72
Increase / Decrease in Other Current Assets	7291.80	-21503.44
Increase / Decrease in Other Non Current Assets	5145.65	-3067.30
Increase / Decrease in Long-term loans and advances	-917.75	28.43
Increase/Decrease in Provision	4974.00	-3038.08
Increase/Decrease in short term liabilities	1528.11	734.08
Increase/Decrease in Current Liability	5384.20	4838.98
<b>Sub Total</b>	10169.17	-81377.82
Cash Generated from Operations	44006.08	-7315.15
Direct Taxes Paid (Net)	14392.03	17725.00
<b>Net Cash inflow in Operating Activities</b> <span style="float: right;"><b>Total A</b></span>	<b>29614.05</b>	<b>-25040.15</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchases of Property, Plant and Equipment	-13935.96	-16133.34
Purchase of Investment	-44656.07	-33845.83
Other Bank Balance	.00	232.00
Capital Government Grant of Property, Plant and Equipment	.00	.00
Loans given to Associates and Subsidiaries	-3073.30	-20730.00
Loans given to Others	.00	-2500.00
Loans received from Holding company	-2620.80	12792.21
Interest Income	650.51	1522.05
Gain on Sale of Investment	.00	.00
Sale of Investment	4323.70	4300.00
<b>Sub Total</b>	-59311.93	-54362.91
<b>Net Cash used in Investing Activities</b> <span style="float: right;"><b>Total B</b></span>	<b>-59311.93</b>	<b>-54362.91</b>



C. Cash Flow from Financing Activities:			
Issue of Equity Capital		.00	19160.00
Share application Money received		51600.00	23500.00
Share Premium		.00	114445.07
Dividend		.00	-3561.40
Proceed of Borrowing		3500.00	.00
issue of Preference Shares		.00	.00
Redemption of Preference shares		-400.00	-4800.00
Repayment of Borrowing		-4720.21	-18610.29
Interest & Finance Charges Paid		-4467.82	-8056.71
		45511.97	122076.69
<b>Net Cash from Financing Activities</b>	<b>Total C</b>	<b>45511.97</b>	<b>122076.69</b>
<b>Net increase /(decrease) in cash and cash equivalents (A+B+C)</b>		<b>15814.10</b>	<b>42673.62</b>
Opening Cash and Cash equivalents		65338.09	22895.86
<b>Closing Cash and Cash equivalents</b>		<b>81152.18</b>	<b>65569.48</b>

**Notes :**

(i) Figures in brackets represent outflow.

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act, 2013

(iii) Cash and Cash Equivalents represent cash and bank balances.

For MAITREYA MEDICARE LIMITED



*Narendra Tanwar*

NARENDRA TANWAR  
DIN - 0008459007  
MD AND CFO



**UTILISATION CERTIFICATE**

To,  
Maitreya Medicare Limited  
(Formerly known as "Maitreya Medicare Private Limited")  
CIN - U24290GJ2019PLC107298

I, Esmayeel Oanali Saherwala, Partner of M/s. Saherwala and Co; Chartered Accountants, hereby certify the the manner of the utilization of issue proceeds of Maitreya Medicare Limited CIN - U24290GJ2019PLC107298 as follows:

Annexure A

Sr. No.	Object as Disclosed in the Offer Document	Amount Disclosed in the Offer Document	Actual utilised Amount (₹ in Lakhs)	Unutilised Amount (₹ in Lakhs)	Remarks
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	750.00	750.00	0	Remaining amount is kept with banks as per certificate of Statutory Auditor of Subsidiary Maitreya Hospital Private Limited
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	100.00	100.00	0	
3	Funding the working capital requirements of the company	500.00	500.00	0	
4	General Corporate Expenses	74.46	74.46	0	
5	Public Issue Expenses	64.66	64.66	0	
	<b>Total</b>	<b>1489.12</b>	<b>1489.12</b>		

The above figures have been verified from the Books of Accounts, registers and allied records maintained by the company. Company has invsted in subsidiary as per object disclosed in offer documents, however as per the certificate issued by Statutory Auditor of Subsidiary Maitreya Hospital Private Limited for item at Sr. No.1, there is unutilised amount which was kept in bank account of Maitreya Hospital Private Limited.

The above certificate is addressed to and provided to the Board of Directors of the Company solely for the purpose of enabling it to comply with its obligations of submitting with National Stock Exchange of India electronic application processing system (NEAPS).

Date: 28.10.2024  
Place: Surat



For Saherwala & Co.  
Chartered Accountants;  
FRN:108969W

CA. Esmayeel Oanali Saherwala  
Partner  
M. No.122386  
UDIN:24122386BKENIE4108